Patents Represented by Attorney David M. Morse
  • Patent number: 4120857
    Abstract: Novel ester and ether derivatives of 1,2,3,3-tetramethyl-2-azabicyclo[2.2.2]octan-5-endo-ol have been prepared and found to possess antiarrhythmic or antihypertensive activity. An example of such a derivative possessing excellent antiarrhythmic activity is 5-endo-(3-benzoylaminopropyloxy)-1,2,3,3-tetramethyl-2-azabicyclo[2.2.2]oc tane.
    Type: Grant
    Filed: April 26, 1977
    Date of Patent: October 17, 1978
    Inventors: Mario Longobardi, Pietro Schenone, Francesco Bondavalli
  • Patent number: 4118566
    Abstract: There is described the stereoselective total synthesis of novel .DELTA..sup.2,3 -1,4-morpholine-2-carboxylic acids possessing a fused .beta.-lactam ring in the 1,6-position and carrying a substituent cis to carbon 5 in the 7-position of the fused ring system represented by the general formula ##STR1## wherein X is amino, azido or acylamido and Z represents optionally substituted C.sub.1 -C.sub.6 alkyl, aryl, aralkyl or heterocyclic. Also included in the invention are compounds of formula I in which the carboxyl group at the 2-position is protected as by an easily cleavable ester group and salts of both the free acids and carboxyl-protected compounds of formula I. The compounds of formula I are potent antibacterial agents or are of use as intermediates in the preparation of such antibacterial agents.
    Type: Grant
    Filed: January 27, 1977
    Date of Patent: October 3, 1978
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Horning, Leeson R. Morris, James L. Douglas
  • Patent number: 4113946
    Abstract: There is described the stereoselective total synthesis by a variety of routes of novel suitably substituted .DELTA..sup.2,3 -1,4-morpholine-2-carboxylic acids possessing a fused .beta.-lactam ring in the 1,6-position and carrying a substituent cis to carbon 5 in the 7-position of the fused ring system represented by the general formula ##STR1## wherein Q is hydrogen, alkyl, aralkyl or --CH.sub.2 COOZ where Z is hydrogen or the residue of an ester group and X is amino, azido or acylamino. Also included in the invention are compounds of the above formula in which the carboxyl group at the 2-position is protected as by an easily cleavable ester group and salts of both the free acids and carboxyl-protected compounds. Those compounds in which X is acylamino and their physiologically hydrolyzed esters and pharmaceutically acceptable salts are potent antibacterial agents.
    Type: Grant
    Filed: January 19, 1977
    Date of Patent: September 12, 1978
    Assignee: Bristol-Myers Company
    Inventors: Bernard R. Belleau, Terrence W. Doyle, Bing Yu Luh, Terry T. Conway
  • Patent number: 4112071
    Abstract: A novel anthracycline antibiotic complex designated herein as figaroic acid complex is produced by fermentation of Streptosporangium sp. strain C-31,751, A.T.C.C. 31129. Figaroic acid complex inhibits the growth of various microorganisms, e.g., Staphylococcus aureus, exhibits phage inducing properties and inhibits the growth of various tumors in rodents, e.g., Sarcoma 180, L-1210 lymphatic leukemia, B-16 melanoma, Walker 256 carcinosarcoma and P-388 lymphatic leukemia.
    Type: Grant
    Filed: September 9, 1977
    Date of Patent: September 5, 1978
    Assignee: Bristol-Myers Company
    Inventors: William T. Bradner, James A. Bush, Donald E. Nettleton, Jr.
  • Patent number: 4112230
    Abstract: There is described the stereoselective total synthesis of novel .DELTA..sup.2,3 -1,4-morpholine-2-carboxylic acids possessing a fused .beta.-lactam ring in the 1,6-position and carrying a substituent cis to carbon 5 in the 7-position of the fused ring system represented by the general formula ##STR1## wherein Z is halo, hydroxyl, etherified hydroxyl or hydroxyl esterified with a carboxylic acid residue or a sulfonic acid residue and X is amino, azido or acylamino. Also included in the invention are compounds of formula I in which the carboxyl group at the 2-position is protected as by an easily cleavable ester group and salts of both the free acids and carboxyl-protected compounds of formula I. The compounds of formula I are potent antibacterial agents or are of use as intermediates in the preparation of such antibacterial agents.
    Type: Grant
    Filed: January 17, 1977
    Date of Patent: September 5, 1978
    Assignee: Bristol-Myers Company
    Inventors: Marcel Menard, Gary M. F. Lim, Terry T. Conway
  • Patent number: 4108725
    Abstract: A novel aminoglycoside antibiotic complex designated herein as Bu-2183 is produced by fermentation of Pseudomonas sp. strain D946-B83, A.T.C.C. 31086. Complex Bu-2183 is known to consist of at least five components, said components being herein designated Bu-2183 A, A.sub.2, B, C and D. The complex and the individual aminoglycoside components Bu-2183 A, A.sub.2, and B are found to have a broad spectrum of antibacterial activity and are especially useful in inhibiting aminoglycoside-resistant organisms including Pseudomonas species.
    Type: Grant
    Filed: August 13, 1976
    Date of Patent: August 22, 1978
    Assignee: Bristol-Myers Company
    Inventors: Hiroshi Kawaguchi, Koji Tomita, Kei-ichi Fujisawa, Hiroshi Tsukiura
  • Patent number: 4082751
    Abstract: A series of 2-(substituted)phenyl-5-(5-1H-tetrazolyl)pyrimidin-4(3H)-ones is provided for use as inhibitors of allergic reactions. The compounds show antiallergy activity by both oral and parenteral routes of administration.
    Type: Grant
    Filed: December 8, 1976
    Date of Patent: April 4, 1978
    Assignee: Bristol-Myers Company
    Inventors: Peter Frederick Juby, Richard Anthony Partyka
  • Patent number: 4081441
    Abstract: The penicillanic acids of the formula ##STR1## wherein Z is an oxygen or sulfur atom and their pharmaceutically acceptable salts and physiologically hydrolyzed esters possess antibacterial activity and are particularly valuable in treating Pseudomonas infections.
    Type: Grant
    Filed: April 6, 1977
    Date of Patent: March 28, 1978
    Assignee: Bristol-Myers Company
    Inventors: Stephen Richard Baker, Charles Truman Holdrege
  • Patent number: 4079057
    Abstract: The quinazoline derivative having the formula ##STR1## and pharmaceutically acceptable salts thereof are selective immunosuppressive agents useful in the treatment of immune complex diseases such as rheumatoid arthritis.
    Type: Grant
    Filed: May 31, 1977
    Date of Patent: March 14, 1978
    Assignee: Bristol-Myers Company
    Inventors: Peter Frederick Juby, Thomas William Hudyma
  • Patent number: 4068075
    Abstract: There is described the stereoselective total synthesis of novel .DELTA..sup.2,3 -1,4-morpholine-2-carboxylic acids possessing a fused .beta.-lactam ring in the 1,6-position and carrying a substituent cis to carbon 5 in the 7-position of the fused ring system represented by the general formula ##STR1## wherein Z is halo, hydroxyl, etherified hydroxyl or hydroxyl esterified with a carboxylic acid residue or a sulfonic acid residue and X is amino, azido or acylamino. Also included in the invention are compounds of formula I in which the carboxyl group at the 2-position is protected as by an easily cleavable ester group and salts of both the free acids and carboxyl-protected compounds of formula I. The compounds of formula I are potent antibacterial agents or are of use as intermediates in the preparation of such antibacterial agents.
    Type: Grant
    Filed: August 19, 1976
    Date of Patent: January 10, 1978
    Assignee: Bristol-Myers Company
    Inventors: Marcel Menard, Gary M. F. Lim, Terry T. Conway
  • Patent number: 4068080
    Abstract: There is described the stereoselective total synthesis of novel .DELTA..sup.2,3 -1,4-morpholine-2-carboxylic acids possessing a fused .beta.-lactam ring in the 1, 6-position and carrying a substituent cis to carbon 5 in the 7-position of the fused ring system represented by the general formula ##STR1## wherein Z is halo, hydroxyl, etherified hydroxyl or hydroxyl esterified with a carboxylic acid residue or a sulfonic acid residue and X is amino, azido or acylamino. Also included in the invention are compounds of formula I in which the carbonyl group at the 2-position is protected as by an easily cleavable ester group and salts of both the free acids and carboxyl-protected compounds of formula I. The compounds of formula I are potent antibacterial agents or are of use as intermediates in the preparation of such antibacterial agents.
    Type: Grant
    Filed: August 19, 1976
    Date of Patent: January 10, 1978
    Assignee: Bristol-Myers Company
    Inventors: Marcel Menard, Gary M. F. Lim, Terry T. Conway
  • Patent number: 4068066
    Abstract: There is described the stereoselective total synthesis of novel .DELTA..sup.2,3 -1,4-morpholine-2-carboxylic acids possessing a fused .beta.-lactam ring in the 1,6-position and carrying a substituent cis to carbon 5 in the 7-position of the fused ring system represented by the general formula ##STR1## wherein X is amino, azido or acylamido and Z represents optionally substituted C.sub.1 -C.sub.6 alkyl, aryl, aralkyl or heterocyclic. Also included in the invention are compounds of formula I in which the carboxyl group at the 2-position is protected as by an easily cleavable ester group and salts of both the free acids and carboxyl-protected compounds of formula I. The compounds of formula I are potent antibacterial agents or are of use as intermediates in the preparation of such antibacterial agents.
    Type: Grant
    Filed: September 23, 1976
    Date of Patent: January 10, 1978
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Horning, Leeson R. Morris, James L. Douglas
  • Patent number: 4068078
    Abstract: There is described the stereoselective total synthesis of novel .DELTA..sup.2,3 -1,4-morpholine-2-carboxylic acids possessing a fused .beta.-lactam ring in the 1,6-position and carrying a substituent cis to carbon 5 in the 7-position of the fused ring system represented by the general formula ##STR1## wherein Z is halo, hydroxyl, etherified hydroxyl or hydroxyl esterified with a carboxylic acid residue or a sulfonic acid residue and X is amino, azido or acylamino. Also included in the invention are compounds of formula I in which the carboxyl group at the 2-position is protected as by an easily cleavable ester group and salts of both the free acids and carboxyl-protected compounds of formula I. The compounds of formula I are potent antibacterial agents or are of use as intermediates in the preparation of such antibacterial agents.
    Type: Grant
    Filed: August 19, 1976
    Date of Patent: January 10, 1978
    Assignee: Bristol-Myers Corporation
    Inventors: Marcel Menard, Gary M. F. Lim, Terry T. Conway
  • Patent number: 4066832
    Abstract: There is described the stereoselective total synthesis of novel .DELTA..sup.2,3 -1,4-morpholine-2-carboxylic acids possessing a fused .beta.-lactam ring in the 1,6-position and carrying a substituent cis to carbon 5 in the 7-position of the fused ring system represented by the general formula ##STR1##wherein Z is halo, hydroxyl, etherified hydroxyl or hydroxyl esterified with a carboxylic acid residue or a sulfonic acid residue and X is amino, azido or acylamino. Also included in the invention are compounds of formula I in which the carboxyl group at the 2-position is protected as by an easily cleavable ester group and salts of both the free acids and carboxyl-protected compounds of formula I. The compounds of formula I are potent antibacterial agents or are of use as intermediates in the preparation of such antibacterial agents.
    Type: Grant
    Filed: August 19, 1976
    Date of Patent: January 3, 1978
    Assignee: Bristol-Myers Company
    Inventors: Marcel Menard, Gary M. F. Lim, Terry T. Conway
  • Patent number: 4066831
    Abstract: There is described the stereoselective total synthesis by a variety of routes of novel suitably substituted .DELTA..sup.2,3 -1, 4-morpholine-2-carboxylic acids possessing a fused .alpha.-lactam ring in the 1,6-position and carrying a substituent cis to carbon 5 in the 7-position of the fused ring system represented by the general formula ##STR1## wherein Q is hydrogen, alkyl, aralkyl or -CH.sub.2 COOZ where Z is hydrogen or the residue of an ester group and X is amino, azido or acylamino. Also included in the invention are compounds of the above formula in which the carboxyl group at the 2-position is protected as by an easily cleavable ester group and salts of both the free acids and carboxyl-protected compounds. Those compounds in which X is acylamino and their physiologically hydrolyzed esters and pharmaceutically acceptable salts are potent antibacterial agents.
    Type: Grant
    Filed: August 19, 1976
    Date of Patent: January 3, 1978
    Assignee: Bristol-Myers Company
    Inventors: Bernard R. Belleau, Terrence W. Doyle, Bing Yu Luh, Terry T. Conway
  • Patent number: 4065622
    Abstract: There is described the stereoselective total synthesis of novel .DELTA..sup.2,3 -1,4-morpholine-2-carboxylic acids possessing a fused .beta.-lactam ring in the 1,6-position and carrying a substituent cis to carbon 5 in the 7-position of the fused ring system represented by the general formula ##STR1## wherein X is amino, azido or acylamido and Z represents optionally substituted C.sub.1 -C.sub.6 alkyl, aryl, aralkyl or heterocyclic. Also included in the invention are compounds of formula I in which the carboxyl group at the 2-position is protected as by an easily cleavable ester group and salts of both the free acids and carboxyl-protected compounds of formula I. The compounds of formula I are potent antibacterial agents or are of use as intermediates in the preparation of such antibacterial agents.
    Type: Grant
    Filed: September 23, 1976
    Date of Patent: December 27, 1977
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Horning, Leeson R. Morris, James L. Douglas
  • Patent number: 4065623
    Abstract: There is described the stereoselective total synthesis by a variety of routes of novel suitably substituted .DELTA..sup.2,3 -1, 4-morpholine-2-carboxylic acids possessing a fused .beta.-lactam ring in the 1,6-position and carrying a substituent cis to carbon 5 in the 7-position of the fused ring system represented by the general formula ##STR1## wherein Q is hydrogen, alkyl, aralkyl or --CH.sub.2 COOZ where Z is hydrogen or the residue of an ester group and X is amino, azido or acylamino. Also included in the invention are compounds of the above formula in which the carboxyl group at the 2-position is protected as by an easily cleavable ester group and salts of both the free acids and carboxyl-protected compounds. Those compounds in which X is acylamino and their physiologically hydrolyzed esters and pharmaceutically acceptable salts are potent antibacterial agents.
    Type: Grant
    Filed: August 19, 1976
    Date of Patent: December 27, 1977
    Assignee: Bristol-Myers Company
    Inventors: Bernard R. Belleau, Terrence W. Doyle, Bing Yu Luh, Terry T. Conway
  • Patent number: 4064014
    Abstract: A novel anthracycline antibiotic complex designated herein as bohemic acid complex is produced by fermentation of Actinosporangium sp. A.T.C.C. 31127. The complex and two bioactive components designated marcellomycin and musettamycin exhibit antibiotic activity and inhibit the growth of various tumor systems in rodents.
    Type: Grant
    Filed: March 23, 1977
    Date of Patent: December 20, 1977
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., James A. Bush, William T. Bradner, Richard H. Schreiber
  • Patent number: 4064234
    Abstract: A composition for treatment of hypercholesterolemia contains clofibrate or a clofibrate derivative, a magnesium or aluminum ion contributing compound which forms substantially insoluble metal bile acid salts and, optionally, a basic anion exchange resin. The composition components combine to give synergistic effect.
    Type: Grant
    Filed: November 26, 1976
    Date of Patent: December 20, 1977
    Assignee: Bristol-Myers Company
    Inventor: Alan N. Howard
  • Patent number: 4051237
    Abstract: A novel water-soluble basic glycopeptide antibiotic complex designated herein as Bu-2231 is produced by fermentation of a Bu-2231-producing strain of Streptoalloteichus hindustanus. Complex Bu-2231 and two of its major components designated herein as Bu-2231 A and B are found to inhibit the growth of various Gram-positive and Gram-negative and acid-fast bacteria as well as certain plant pathogens. The complex and components Bu-2231 A and B are also useful in inhibiting the growth of various tumors in rodents, for example, Walker 256 carcinosarcoma and Lewis Lung carcinoma.
    Type: Grant
    Filed: August 28, 1975
    Date of Patent: September 27, 1977
    Assignee: Bristol-Myers Company
    Inventors: Hiroshi Kawaguchi, Koji Tomita, Hiroshi Tsukiura, Masataka Konishi